ATAI Life Sciences

atai's Phase 1 Synthetic DMT-Based Drug Clinical Trial Begins Patient Dosing
Atai Life Sciences: Capital Raise, Share Options, Cathie Wood And More On Biotech Psychedelics Leader
ATAI Life Sciences Present A "New Recipe For Success" At The Psychedelic Capital Conference
Sponsored
Atai Life Sciences: Capital Raise, Share Options, Cathie Wood And More On Biotech Psychedelics Leader
ATAI Life Sciences Present A "New Recipe For Success" At The Psychedelic Capital Conference
Sponsored
atai Life Sciences Announces Fourth Quarter and Full Year 2021 Financial Results
National Institute on Drug Abuse Will Test Ibogaine For Addiction Treatment As Drug Deaths Crest 100,000

ATAI Life Sciences Recent News

This Psychedelics Stock Was Up More Than 20% Last Week, Outperforming Tesla, Nvidia and GameStop
Psychedelics have picked up more and more momentum on Wall Street, with famed investors such as Kevin O’Leary and
Psyched: MindMed and Atai Head For Nasdaq, Psychedelics Search Platforms Grow, Champignon Brands Gets Back To Trading
Two of the most highly funded companies in the psychedelics space announced plans last week to list on the Nasdaq exchange.
Worthy Or Superfluous? Psychedelics Experts Discuss The Sector's Ongoing Patent Debate
Co-written by Andrew Ward and Natan Ponieman The race is continually heating up in the psychedelics space. An array of companies, educational institutions and investors have already obtained patents on formulations, processes, compounds and other aspects of psychedelics treatment.
Psychecelics Company Atai Life Sciences Files For Nasdaq Listing In Sector's Highly Anticipated IPO
Atai Life Sciences could soon become the second psychedelics company to list on a major U.S. exchange. The Berlin-based biotech firm filed Tuesday with the SEC to raise $100 million in an IPO using the ticker symbol "ATAI."
Psyched: Entheon Launches Psychedelics Genetic Test, Mydecine Unveils Psychedelic Drug Candidates, California Bill Passes Senate Committee
Entheon Biomedical Corp. announced the launch of a psychedelics genetic test kit last week through its wholly owned subsidiary HaluGen Life Sciences Inc.
Psyched: Novamind Partners With Merck, Atai Expands To Japan, Australia Funds Psychedelics Research
Novamind Strikes Research Deal With Merck
Psyched: The Patents Dilemma, Compass 2020 Earnings, New Psilocybin Bill In NY
These days, the psychedelics finds itself in the midst of a public debate around the moral implications of patents and intellectual property for certain medicines and treatments.
Psyched: Atai Raises $157M, Silo Wellness Goes Public, Mydecine Completes Export Of 'Magic Mushrooms'
Atai Inks Largest Fundraise In Sector History With $157M Series D Psychedelics and mental health company Atai Life Sciences has raised $157 million in venture capital.
Psychedelics Startup Atai Inks Largest Fundraise In Sector History With $157M Series D
Psychedelics and mental health company Atai Life Sciences has raised $157 million in venture capital. The Series D funding round is being touted as the psychedelics sector’s largest to date.
Psyched: First Psychedelics ETF Debuts; Hawaii, Florida and Connecticut Eye Psilocybin Legalization; Psyence Goes Public
First Psychedelics ETF Debuts On NEO Exchange Psychedelics’ first exchange traded fund went public last Wednesday.
Atai Partners With Harvard's Massachusetts General Hospital For Psychedelics Research
Atai Life Sciences t announced on Tuesday a new research collaboration with Massachusetts General Hospital, the largest teaching hospital of Harvard Medical School.
Psyched: Compass Launches Center Of Excellence, Entheon Purchases HaluGen, Atai Buys Majority Stake In Recognify
Compass Launches Center Of Excellence Compass Pathways (NASDAQ: CMPS) officially launched the Centre of Excellence, in collaboration with The Sheppard Pratt Institute for Advanced Diagnostics and Therapeutics in Baltimore, Maryland.
Psyched: MindMed Launches DTx Division, ATAI Closes $125M Series C, Novamind Raises CA$10M
Novamind Raises CA$10M, Heads Towards CSE Listing Toronto-based psychedelics company Novamind Ventures announced the closing of a private placement for CA$10 million ($7.6 million).
Psyched: Compass Joins Nasdaq, Field Trip Goes Public, MindMed Begins Trials, ATAI Launches MDMA Subsidiary
Compass Pathways Files for an IPO at NASDAQ UK-based Compass Pathways wants to become the first psychedelics company to list on a major U.S. stock exchange. The psilocybin research company intends to make its initial public offering (IPO) through NASDAQ under the ticker symbol CMPS.
ATAI Launches Subsidiary To Develop MDMA Derivatives
Psychedelics and biotech company ATAI Life Sciences announced on Monday the launch of a new subsidiary that will focus on the development of MDMA derivatives for the treatment of post-traumatic stress disorder and other indications. EmpathBio will be a wholly owned subsidiary of ATAI, led by CEO Glenn Short.
'Psyched': Atai Launches DMT Subsidiary, NeuroPharm Collaborates With Dutch University
ATAI Launches Subsidiary Focused on DMT
ATAI Launches Subsidiary Focused On Active Ingredient In Hallucinogenic Brews
Psychedelics and biotech company ATAI Life Sciences announced Wednesday the launch of Viridia Life Sciences. This wholly-owned subsidiary will be dedicated to the study and production of the DMT molecule (N,N-Dimethyltryptamine).
'Psyched': Atai Buys Kures, Beckley Psytech Raises $3.7M, Mydecine Acquires NeuroPharma
PSYCHED is now weekly! As the psychedelics industry grows, so does the need for news. For this reason, our column covering the most important developments in medicinal psychedelics is now a weekly feature. 
Thiel Capital's Jason Camm Discusses Joining Psychedelics Company ATAI Following $24 Million Raise
Earlier this year, ATAI Life Sciences, a biotech company developing psychedelic medicines for a variety of mental health indication, announced that it had raised $24 million in a convertible note financing round.
'Psyched': Military Invests $27M In Psychedelic Research, Atai Launches DTx Platform, Psilocybin Decriminalization Rejected In Iowa
Psyched is a bimonthly column covering the most important developments in the industry of medicinal psychedelics. We hope you follow us periodically as we report on the growth of this exciting new industry.
'Psyched': New Leaf Brands Changes Name To Mydecine, Numinus Debuts On TSXV, MindMed To Research MDMA-LSD Interactions
Psyched is a bi-monthly column covering the most important developments in the industry of medicinal psychedelics. We hope you follow us periodically as we report on the growth of this exciting new industry.
'Psyched': ATAI Closes $24M Convertible Round, MindMed To Begin Trading On OTCQB, Investor Presentations Available Online
Psyched is a bi-monthly column covering the most important developments in the industry of medicinal psychedelics. We hope you follow us periodically as we report on the growth of this exciting new industry.
Arketamine: A Fast-Acting Antidepressant Without Dissociative Effects?